pedunculoside: from leaves of Ilex chinensis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Ilex | genus | A plant genus of the family AQUIFOLIACEAE. The common name of 'holly' usually refers to this genus but may sometimes refer to similar looking plants of the MAHONIA or QUERCUS genus.[MeSH] | Aquifoliaceae | The holly plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 14286954 |
| CHEMBL ID | 508539 |
| MeSH ID | M0223905 |
| Synonym |
|---|
| CHEMBL508539 |
| pedunculoside |
| S9501 |
| 42719-32-4 |
| urs-12-en-28-oic acid, 3,19,23-trihydroxy-, beta-d-glucopyranosyl ester, (3beta,4alpha)- |
| [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1r,2r,4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate |
| AKOS037514772 |
| HY-N0458 |
| (2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl (1r,2r,4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2 |
| mfcd01632712 |
| CCG-270330 |
| CS-0008985 |
| DTXSID30962647 |
| 1-o-(3,19,23-trihydroxy-28-oxours-12-en-28-yl)hexopyranose |
| AS-56458 |
| (3beta,4alpha)-3,19,23-trihydroxy-urs-12-en-28-oic acid beta-d-glucopyranosyl ester |
| A872833 |
Pedunculoside (PE) is a novel triterpene saponin extracted from the dried barks of Ilex rotunda Thunb.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pedunculoside (PE) is a novel triterpene saponin extracted from the dried barks of Ilex rotunda Thunb. " | ( Pedunculoside, a novel triterpene saponin extracted from Ilex rotunda, ameliorates high-fat diet induced hyperlipidemia in rats. Guo, H; Liu, C; Shen, YJ; Shi, HW; Sun, Y; Tu, QB; Wang, J; Zhang, L; Zhao, YR, 2018) | 3.37 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pedunculoside has been used to treat myocardial ischemia, ameliorate hyperlipidemia and prevent liver injury." | ( LC-Q-TOF/MS-oriented systemic metabolism study of pedunculoside with in vitro and in vivo biotransformation. Bian, Y; Chai, C; Kang, A; Lin, Y; Shan, C; Wu, L; Zhou, Z, 2019) | 1.49 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The validated method was successfully applied to the pharmacokinetic study of PDC in rat plasma after oral administration of pure PDC and Ilex rotunda extract (IRE)." | ( LC-MS/MS Determination and Pharmacokinetic Study of Pedunculoside in Rat Plasma after Oral Administration of Pedunculoside and Ilex rotunda Extract. Pang, L; Xu, D; Zhang, N; Zhao, W, 2015) | 0.67 |
| " Although many studies about the total saponins have been reported, the absorption triterpenoids and pharmacokinetic behaviors were unclear." | ( Rapid profiling and pharmacokinetic studies of multiple potential bioactive triterpenoids in rat plasma using UPLC/Q-TOF-MS/MS after oral administration of Ilicis Rotundae Cortex extract. Jin, J; Li, H; Liu, Z; Ruan, Q; Tong, Y; Xuan, S; Yang, B; Zhao, Z, 2018) | 0.48 |
| " In this study, we evaluated the pharmacokinetic interactions of rotundic acid with pedunculoside and other ingredients from Ilicis Rotundae Cortex with rotundic acid and pedunculoside, and preliminarily investigated the effects of gut microbiota on their pharmacokinetics using a pseudo-germ-free rat model." | ( Effects of Gut Microbiota and Ingredient-Ingredient Interaction on the Pharmacokinetic Properties of Rotundic Acid and Pedunculoside. Chen, X; Cui, H; Jin, J; Li, H; Liu, Z; Ruan, Q; Xuan, S; Yang, B; Zhao, Z, 2019) | 0.95 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "More than 50% of new drug candidates in drug discovery are lipophilic and exhibit poor aqueous solubility, which results in poor bioavailability and a lack of dose proportionality." | ( A water-soluble inclusion complex of pedunculoside with the polymer β-cyclodextrin: a novel anti-inflammation agent with low toxicity. Diao, G; Gong, X; Liu, C; Sun, W; Sun, Y; Yang, H; Zhang, W; Zhao, J, 2014) | 0.68 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1070421 | Inhibition of NF-kappaB activity in TNF-alpha stimulated human HEK-293/NF-kB-luc cells incubated for 30 mins prior to TNF-alpha challenge for 4 hrs by luciferase reporter gene assay | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | NF-κB inhibitors from Eurycoma longifolia. |
| AID1090564 | Antiviral activity against Tobacco mosaic virus (TMV) inoculated in Nicotiana tabacum cv. K326 leaves assessed as inhibition of virus multiplication at 0.2 mg/ml at 25 degC measured after 48 hr by indirect ELISA/leaf-disk method | 2007 | Journal of agricultural and food chemistry, Mar-07, Volume: 55, Issue:5 | Anti-tobacco mosaic virus (TMV) triterpenoid saponins from the leaves of Ilex oblonga. |
| AID1070420 | Growth inhibition of TNF-alpha stimulated human HEK-293/NF-kB-luc cells assessed as cell viability at 30 uM incubated for 30 mins prior to TNF-alpha challenge for 4 hrs by CellTracker Green CMFDA staining | 2014 | Journal of natural products, Mar-28, Volume: 77, Issue:3 | NF-κB inhibitors from Eurycoma longifolia. |
| AID333388 | Antitrypanosomal activity against Trypanosoma brucei S427 by microdilution method | 2004 | Journal of natural products, Oct, Volume: 67, Issue:10 | Triterpenoids from Brazilian Ilex species and their in vitro antitrypanosomal activity. |
| AID333387 | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 by microdilution method | 2004 | Journal of natural products, Oct, Volume: 67, Issue:10 | Triterpenoids from Brazilian Ilex species and their in vitro antitrypanosomal activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||